Visit Contract Pharma
at Booth #1921

Metrics Expands Granulation Capabilities

11.01.18

Adds Gerteis Mini-Pactor roller compactor at its oral solid dose commercial manufacturing facility in Greenville, NC

Metrics Contract Services, a division of Mayne Pharma Group Ltd., has added a Gerteis Mini-Pactor roller compactor to its granulation capabilities at its new $80 million oral solid dose commercial manufacturing facility in Greenville, NC. Metrics had purchased its initial Gerteis Mini-Pactor in 2014 for dry granulation development and clinical manufacturing services.
 
The Gerteis Mini-Pactor allows optimization within a range of press forces, roller speeds, and gap settings using knurled, smooth, toothed or custom rollers with a production output of up to 100kg/hr. These roller compactors will now be used for early phase formulation development, clinical trial production through to commercial manufacture.
 
The company’s recently opened manufacturing facility in Greenville also includes newly purchased equipment from manufacturers such as Glatt, Thomas, O’Hara and IMA. Metrics now has capabilities for clinical and commercial scale, solvent capable, fluid-bed processing and film coating, wet granulation, tableting, encapsulation, and pan-coating. The new facility more than quadruples the company’s capacity to manufacture oral solid dose pharmaceuticals products to more than 1 billion doses and increases capacity to manufacture potent compounds. 
 
Metrics’ executive vice president Kimberly McClintock said, “With completion of our new commercial manufacturing facility and the success of our client’s clinical programs, it was time to add a second Gerteis roller compactor for use in commercial production. Based on the anticipated lot size and annual demand of the products progressing toward commercialization, the Mini-Pactor was the right choice for throughput and ease of tech transfer to commercial production. This supports our strategy to be a leading small molecule oral dosage form producer for targeted specialty medicines being developed today.”